Accueil
Marchés
Graphique & Idées
Algo
Nouvelles
Store
Courtiers
Télécharger
Calendrier Economique
Signaux de trading
Terminal Web
Tapez
/
pour rechercher : @user, $symbol
Recherche
Se connecter
Créer un compte
Français
English
Русский
中文
Español
Português
日本語
Deutsch
한국어
Italiano
Türkçe
SUPN
#1402
Supernus Pharmaceuticals, Inc.
54.730
0
+0.48%
Secteur:
Base:
Devise de Profit:
Range quotidien
Range Annuel
Changement quotidien
+0.48%
Changement Mensuel
+10.77%
Evolution sur 6 mois
+1.35%
Changement Annuel
+1.35%
Clôture Précédente
54.470
0
Open
54.730
0
Bid
Ask
Low
54.730
0
High
54.730
0
Volume
97
Marchés
Actions des Marchés US
Soins de Santé
SUPN
Open full chart
Financials
Overview
Relevé
Statistics
Dividends
Quarterly
Annual
Value
2020
2021
2022
2023
2024
TTM
Key stats
Total common shares outstanding
52.92 M
53.39 M
54.38 M
54.73 M
55.81 M
—
Valuation ratios
Enterprise value
1.04 B
1.35 B
1.94 B
1.44 B
1.95 B
7.88 B
Price to earnings ratio
10.66
29.76
36.03
1 386.5
27.39
-56.25
Price to sales ratio
2.6
2.73
3.46
2.53
3.06
12.4
Price to cash flow ratio
9.76
12.47
19.78
13.86
11.77
69.6
Price to book ratio
1.81
1.94
2.61
1.67
1.95
3.48
Enterprise value to EBITDA ratio
5.08
9.7
3.7
3.14
3.57
34.66
Profitability ratios
Return on assets %
0.08
0.03
0.04
0
0.05
0
Return on equity %
0.17
0.07
0.07
0
0.07
0
Return on invested capital %
56.82
21.61
12.96
0.78
22.24
11.91
Gross margin %
89.92
87.05
86.93
86.21
88.23
354.45
Operating margin %
33.38
14.84
6.91
0.87
12.34
19.1
EBITDA margin %
39.42
24.06
78.86
75.63
82.45
90.12
Net margin %
24.39
9.21
9.1
0.22
11.16
0.27
Liquidity ratios
Quick ratio
2.37
1.63
0.93
1.43
2.16
8.32
Current ratio
2.57
1.91
1.07
1.7
2.35
9.16
Inventory turnover
1.4
1.12
0.98
0.99
1.18
1.36
Asset turnover
0.39
0.36
0.39
0.41
0.5
0.5
Solvency ratios
Debt to assets ratio
—
—
—
—
—
—
Debt to equity ratio
—
—
—
—
—
—
Long term debt to total assets ratio
0.24
0.22
0
0
—
—
Long term debt to total equity ratio
0.49
0.46
0
0
—
—
Per share metrics
Operating cash flow per share
2.58
2.34
1.89
2
3.07
1.28
EBIT per share
3.48
1.97
7.14
6.75
8.31
1.08
EBITDA per share
3.82
2.57
8.53
8.28
9.75
2.6
Total debt per share
—
—
—
—
—
—
Cash per share
7.87
6.25
7.48
4.59
1.24
8.56
Net current asset value per share
11.74
11.07
11.9
8.88
12.26
48.18
Tangible book value per share
5.64
-1.59
1.08
3.69
7.09
28.14
Working capital per share
7.18
5.27
0.75
3.66
7.04
26.97
Book value per share
13.87
15.01
14.37
16.6
18.51
74.43
Nouvelles
TD Cowen relève l’objectif de cours de Supernus Pharmaceuticals suite au relancement d’Onapgo
TD Cowen raises Supernus Pharmaceuticals stock price target on Onapgo relaunch
L’action Supernus Pharmaceuticals atteint un sommet de 52 semaines à 57,76$
Supernus Pharmaceuticals stock hits 52-week high at $57.76
Cantor Fitzgerald réitère sa note de surpondération sur Supernus grâce aux gains d’approvisionnement
Cantor Fitzgerald reiterates Supernus stock Overweight on supply gains
Supernus Pharmaceuticals (SUPN) Surpasses Q4 Earnings and Revenue Estimates
Le BPA de Supernus a manqué les attentes de 0,48$, le CA a surpassé les prévisions
Supernus earnings missed by $0.48, revenue topped estimates
Supernus face au test des résultats après le choc de rentabilité du T3
Supernus faces earnings test after Q3 shock to profitability
Earnings Preview: Supernus Pharmaceuticals (SUPN) Q4 Earnings Expected to Decline